Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

BriaCell Therapeutics Corp. Warrant BCTXZ NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • CA • USD

SharesGrow Score
42/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

BriaCell Therapeutics Corp. Warrant (BCTXZ) is a Biotechnology company in the Healthcare sector, currently trading at $0.13. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Valuation: BCTXZ trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25).

Net income is $36M (loss), growing at -187%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $25M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.01 (strong liquidity). Debt-to-assets is 0%. Total assets: $22M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

BCTXZ SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BCTXZ

✓
VALUE Pass
100/100
BCTXZ trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25). Trailing PEG 0.11. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
BCTXZ: +0%/yr revenue is, -187%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet BCTXZ: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.01 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
BCTXZ: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.1011-0.11
Volume4.02K
Avg Volume (30D)17.68K
Market Cap$244.89K
Beta (1Y)1.63
Share Statistics
EPS (TTM)-86.25
Shares Outstanding$423.11K
IPO Date2025-04-25
Employees16
CEOWilliam V. Williams
Financial Highlights & Ratios
Gross Profit$-147.89K
EBITDA$-36.63M
Net Income$-36.5M
Operating Income$-37.73M
Total Cash$17.87M
Net Debt$-10.49M
Total Assets$21.65M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryCA
ExchangeNASDAQ Global Select
CurrencyUSD
ISINCA1079301174

Price Chart

Track all markets on TradingView
BCTXZ
BriaCell Therapeutics Corp. Warrant ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.10 52WK RANGE 0.11

People Also View

ELAB
ELAB
PMGC Holdings Inc.
$4.20
-4.11%
 NKGN
NKGN
NKGen Biotech, Inc. Common Stock
$0.06
+166.67%
 AIMD
AIMD
Ainos, Inc.
$1.61
-2.42%
 MLEC
MLEC
Moolec Science S.A.
$7.41
-6.68%
 ATXI
ATXI
Avenue Therapeutics, Inc.
$0.51
+14.17%
 NCEL
NCEL
NewcelX Ltd.
$2.50
-0.79%
 DRMA
DRMA
Dermata Therapeutics, Inc.
$1.26
+0.80%
 VRAX
VRAX
Virax Biolabs Group Limited
$0.15
+1.15%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message